m-RNA Synthesis Service Market, By Application (Therapeutic Development, Vaccine Production, Drug Discovery, Others), By Scale of Operation (Research, Commercial), By End User (Biopharmaceutical Companies, Contract research organizations (CROs), Others),

m-RNA Synthesis Service Market, By Application (Therapeutic Development, Vaccine Production, Drug Discovery, Others), By Scale of Operation (Research, Commercial), By End User (Biopharmaceutical Companies, Contract research organizations (CROs), Others), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Messenger RNA (mRNA) synthesis, using DNA as the template, is called transcription. The mRNA carries the genetic information from the chromosomes' DNA in the nucleus to the surface of the cytosol. mRNA is a flexible tool that is utilized for gene editing, cell therapy, vaccinations, and therapeutic protein replacement, among other . The ability to introduce any protein via mRNA enables the cellular production of gene editing tools or antigens.

mRNA is a single-stranded RNA molecule that is complementary to one of a gene's DNA strands. Synthetic mRNAs are used to investigate protein-mediated mRNA recognition, mRNA export and translation, and mutation effects on protein-coding genes. Recently, mRNA-based medicines have been developed for the treatment of various diseases including respiratory, cardiac, metabolic and autoimmune diseases, as well as cancer, cancer immunotherapy, and preventive vaccinations.

Market Dynamics

Increasing number of acquisitions between market players is expected to drive the market growth over the forecast period. For instance, in January 2022, Maravai LifeSciences, Inc., a global provider of life science reagents and services to researchers and biotech innovators, announced that it has acquired MyChem, LLC, company focused on making ultra-pure nucleotides, for US$ 240 million. This acquisition will expand Maravai’s product offering of strategic inputs in the rapidly growing markets for mRNA therapeutics and vaccine applications.

Increasing investments for m-RNA based technologies for m-RNA synthesis by the key players in the market in order to expand their product portfolio is expected to drive the market growth over the forecast period. For instance, in December 2021, Direxion, a financial corporation, announced the launch of the Direxion mRNA ETF, a new exchange-traded fund (ETF) that focuses on the applications and developments of messenger RNA technology. This fund seeks to invest in firms that are developing and applying mRNA technology.

Key features of the study:

• This report provides in-depth analysis of the global m-RNA synthesis service market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global m-RNA synthesis service market based on the following parameters-company highlights, products portfolio, key highlights, financial performance, and strategies. Key companies covered as a part of this study include Maravai LifeSciences, Azenta US, Inc., Creative Biolabs, Becton, Dickinson And Company, Creative Biogene, Kaneka Corporation, Danaher, eTheRNA, Biomay AG, ApexBio Technology, RiboPro, F. Hoffmann-La Roche Ltd, System Biosciences, LLC., Aurigene Pharmaceutical Services Ltd., OZ Biosciences, Aldevron and GenScript
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global m-RNA synthesis service market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global m-RNA synthesis service market

Detailed Segmentation:

• Global m-RNA Synthesis Service Market, By Application:
• Therapeutic Development
• Vaccine Production
• Drug Discovery
• Others
• Global m-RNA Synthesis Service Market, By Scale of Operation:
• Research
• Commercial
• Global m-RNA Synthesis Service Market By End User:
• Biopharmaceutical Companies
• Contract research organizations (CROs)
• Others
• Global m-RNA Synthesis Service Market, By Region:
• North America
• By Country:
• U.S.
• Canada
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country:
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country:
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country:
• GCC
• Israel
• Rest of Middle East
• Africa
• By Country/Region:
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Maravai LifeSciences*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Azenta US, Inc.
• Creative Biolabs
• Becton, Dickinson And Company
• Creative Biogene
• Kaneka Corporation
• Danaher
• eTheRNA
• Biomay AG
• ApexBio Technology
• RiboPro
• F. Hoffmann-La Roche Ltd
• System Biosciences, LLC.
• Aurigene Pharmaceutical Services Ltd.
• OZ Biosciences
• Aldevron
• GenScript

“*” marked represents similar segmentation in other categories in the respective section.